tetano
Editor, Senior Moderator
NPJ Vaccines
. 2023 Feb 13;8(1):13.
doi: 10.1038/s41541-023-00612-2.
Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
Paulina Kaplonek[SUP] #[/SUP][SUP] 1 [/SUP], Deniz Cizmeci[SUP] #[/SUP][SUP] 1 [/SUP], Jessica Shih-Lu Lee[SUP] 1 [/SUP], Sally A Shin[SUP] 1 [/SUP], Stephanie Fischinger[SUP] 1 [/SUP], Philipe Gobeil[SUP] 2 [/SUP], Stéphane Pillet[SUP] 2 [/SUP], Nathalie Charland[SUP] 2 [/SUP], Brian J Ward[SUP] 3 4 [/SUP], Galit Alter[SUP] 5 [/SUP]
Affiliations
Abstract
Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urgent need to develop new durable vaccine candidates, to expand the global vaccine pipeline, and provide safe and effective solutions for every country worldwide. Here we deeply profiled the functional humoral response induced by two doses of AS03-adjuvanted and non-adjuvanted plant-derived Coronavirus-like particle (CoVLP) vaccine candidate from the phase 1 clinical trial, at peak immunogenicity and six months post-vaccination. AS03-adjuvanted CoVLP induced robust and durable SARS-CoV-2 specific humoral immunity, marked by strong IgG1antibody responses, potent FcγR binding, and antibody effector function. Contrary to a decline in neutralizing antibody titers, the FcγR2A-receptor binding capacity and antibody-mediated effector functions, such as opsonophagocytosis, remained readily detectable for at least six months.
. 2023 Feb 13;8(1):13.
doi: 10.1038/s41541-023-00612-2.
Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19
Paulina Kaplonek[SUP] #[/SUP][SUP] 1 [/SUP], Deniz Cizmeci[SUP] #[/SUP][SUP] 1 [/SUP], Jessica Shih-Lu Lee[SUP] 1 [/SUP], Sally A Shin[SUP] 1 [/SUP], Stephanie Fischinger[SUP] 1 [/SUP], Philipe Gobeil[SUP] 2 [/SUP], Stéphane Pillet[SUP] 2 [/SUP], Nathalie Charland[SUP] 2 [/SUP], Brian J Ward[SUP] 3 4 [/SUP], Galit Alter[SUP] 5 [/SUP]
Affiliations
- PMID: 36781879
- DOI: 10.1038/s41541-023-00612-2
Abstract
Despite the success of existing COVID-19 vaccine platforms, the persistent limitations in global deployment of vaccines and waning immunity exhibited by many of the currently deployed vaccine platforms have led to perpetual outbreaks of SARS-CoV-2 variants of concern. Thus, there is an urgent need to develop new durable vaccine candidates, to expand the global vaccine pipeline, and provide safe and effective solutions for every country worldwide. Here we deeply profiled the functional humoral response induced by two doses of AS03-adjuvanted and non-adjuvanted plant-derived Coronavirus-like particle (CoVLP) vaccine candidate from the phase 1 clinical trial, at peak immunogenicity and six months post-vaccination. AS03-adjuvanted CoVLP induced robust and durable SARS-CoV-2 specific humoral immunity, marked by strong IgG1antibody responses, potent FcγR binding, and antibody effector function. Contrary to a decline in neutralizing antibody titers, the FcγR2A-receptor binding capacity and antibody-mediated effector functions, such as opsonophagocytosis, remained readily detectable for at least six months.